Trial Profile
A Phase 1, First-in-Human, 2-Part, Multicenter Dose Escalation and Repeat Dose Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Mar 2021
Price :
$35
*
At a glance
- Drugs TAK 101 (Primary)
- Indications Coeliac disease
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Takeda
- 12 Mar 2021 Results of phase 1 and phase 2a studies assessing safety, tolerability, pharmacokinetics, and efficacy of TAK-101 from the induction of gliadin specific T-cell tolerance in patients with biopsy confirmed CeD, published in the Gastroenterology.
- 18 Jun 2019 Status changed from active, no longer recruiting to completed.
- 29 Jan 2019 Planned End Date changed from 1 Mar 2019 to 29 May 2019.